|Bid||35.76 x 800|
|Ask||35.91 x 800|
|Day's range||35.55 - 36.59|
|52-week range||31.32 - 49.39|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2022|
|Forward dividend & yield||1.04 (2.47%)|
|Ex-dividend date||02 Jun 2022|
|1y target est||N/A|
The FDA schedules a joint advisory committee meeting in November 2022 to review Perrigo's (PRGO) regulatory filing for the first-ever over-the-counter birth control pill.
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.